Publications by authors named "Cathye Shu"

Claim this Profile
C
Content validity and meaningful change for the FACIT-Fatigue scale in warm autoimmune hemolytic anemia: results from qualitative interview studies with patients.
Sheryl Pease, Rikki Mangrum, Karolina Schantz, Christina Slota, Lindsey Rubin, Cathye Shu

J Patient Rep Outcomes· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of guselkumab in patients with active lupus nephritis: results from a phase 2, randomized, placebo-controlled study.
Hans-Joachim Anders, Tak Mao Chan, Jorge Sanchez-Guerrero, David Wofsy, Karen Bensley, Cathye Shu

Rheumatology (Oxford)· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Healthcare resource utilization of patients with warm autoimmune hemolytic anemia initiating first line therapy of oral corticosteroids with or without rituximab.
Irina Murakhovskaya, Concetta Crivera, Ann Leon, Evo Alemao, Vamshi Ruthwik Anupindi, Cathye Shu

Ann Hematol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus.
Ronald F van Vollenhoven, Kenneth C Kalunian, Thomas Dörner, Bevra H Hahn, Yoshiya Tanaka, Cathye Shu

Ann Rheum Dis· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The first-in-human study of CNTO 7160, an anti-interleukin-33 receptor monoclonal antibody, in healthy subjects and patients with asthma or atopic dermatitis.
Ivo Nnane, Bart Frederick, Zhenling Yao, Donald Raible, Cathye Shu

Br J Clin Pharmacol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating Potential Disease-Mediated Protein-Drug Interactions in Patients With Moderate-to-Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab.
Yaowei Zhu, Yan Xu, Yanli Zhuang, Alexa Piantone, Cathye Shu

Clin Transl Sci· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated population pharmacokinetics of etanercept in healthy subjects and in patients with rheumatoid arthritis and ankylosing spondylitis.
Simon Y Zhou, Cathye Shu, Joan Korth-Bradley, Donald Raible, Maria Palmisano

J Clin Pharmacol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic-pharmacodynamic modeling of apratastat: a population-based approach.
Cathye Shu, Honghui Zhou, Mehri Afsharvand, Larry Duan, Hui Zhang

J Clin Pharmacol· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: a Phase I, open-label, dose-escalation clinical study.
Daniel J Burge, Stephen A Bookbinder, Alan J Kivitz, Roy M Fleischmann, Cathye Shu

Clin Ther· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis